Helga Hagman

knuten till universitetet, Dr Med
Fler filtreringsmöjligheter
  1. 2019
  2. Cost analysis comparison between peripherally inserted central catheters and implanted chest ports in patients with cancer—A health economic evaluation of the PICCPORT trial

    Knut Taxbro, Fredrik Hammarskjöld, David Juhlin, Helga Hagman, Lars Bernfort & Sören Berg, 2019 nov 12, I : Acta Anaesthesiologica Scandinavica.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  3. 2018
  4. 2017
  5. A targeted approach to maintenance of tumour response. Clinical and translational studies in metastatic colorectal cancer.

    Helga Hagman, 2017, Lund: Lund University: Faculty of Medicine. 127 s.

    Forskningsoutput: AvhandlingDoktorsavhandling (sammanläggning)

  6. 2016
  7. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

    Helga Hagman, Jan-Erik Frödin, Åke Berglund, Jan Sundberg, Lene Vestermark, Maria Albertsson, Eva Fernebro & Anders Johnsson, 2016 jan, I : Annals of Oncology. 27, 1, s. 140-147

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  8. 2013
  9. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial.

    Anders Johnsson, Helga Hagman, Jan-Erik Frödin, Åke Berglund, N. Keldsen, Eva Fernebro, J Sundberg, R De Pont Christensen, K-L Garm Spindler, D Bergström & A Jakobsen, 2013, I : Annals of Oncology. 24, 9, s. 2335-2341

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift